Terms: = Breast cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
76 results:
1. The relationship between cancer associated fibroblasts biomarkers and prognosis of breast cancer: a systematic review and meta-analysis.
Cui M; Dong H; Duan W; Wang X; Liu Y; Shi L; Zhang B
PeerJ; 2024; 12():e16958. PubMed ID: 38410801
[TBL] [Abstract] [Full Text] [Related]
2. n-3 PUFAs synergistically enhance the efficacy of doxorubicin by inhibiting the proliferation and invasion of breast cancer cells.
Gurav P; Patade T; Hajare S; Kedar RN
Med Oncol; 2023 Nov; 41(1):2. PubMed ID: 38017288
[TBL] [Abstract] [Full Text] [Related]
3. Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative breast cancer Cells.
Agnello L; d'Argenio A; Caliendo A; Nilo R; Zannetti A; Fedele M; Camorani S; Cerchia L
Cells; 2023 Jul; 12(13):. PubMed ID: 37443843
[TBL] [Abstract] [Full Text] [Related]
4. RUNX1 Is Regulated by Androgen Receptor to Promote cancer Stem Markers and Chemotherapy Resistance in Triple Negative breast cancer.
Fernández NB; Sosa SM; Roberts JT; Recouvreux MS; Rocha-Viegas L; Christenson JL; Spoelstra NS; Couto FL; Raimondi AR; Richer JK; Rubinstein N
Cells; 2023 Jan; 12(3):. PubMed ID: 36766786
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptome Profiling of Cisplatin Resistance in Triple-negative breast cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of iron metabolism disorders and adequate treatment of anemic syndrome in patients with breast cancer on the background of adjuvant chemotherapy.
Blindar VN; Zubrikhina GN; Davydova TV; Dobrovolskaya MM; Khagazheeva MN; Snegovoy AV; Lyubimova NV; Kushlinskii NE; Ryabchikov DA
Klin Lab Diagn; 2022 Apr; 67(4):213-218. PubMed ID: 35575394
[TBL] [Abstract] [Full Text] [Related]
7. Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro.
Vashum Y; Premsingh R; Kottaiswamy A; Soma M; Padmanaban A; Kalaiselvan P; Samuel S
Mol Biol Rep; 2021 Jan; 48(1):105-116. PubMed ID: 33294960
[TBL] [Abstract] [Full Text] [Related]
8. Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes.
Del Gaudio F; Guerrera IC; Riccio R; Monti MC
Mol Omics; 2020 Feb; 16(1):19-30. PubMed ID: 31859329
[TBL] [Abstract] [Full Text] [Related]
9. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
10. Tumor-Contacted Neutrophils Promote Metastasis by a CD90-timp-1 Juxtacrine-Paracrine Loop.
Wang Y; Chen J; Yang L; Li J; Wu W; Huang M; Lin L; Su S
Clin Cancer Res; 2019 Mar; 25(6):1957-1969. PubMed ID: 30482778
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Influence of Tumor Stroma on breast cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract] [Full Text] [Related]
12. Erythropoietin Induces an Epithelial to Mesenchymal Transition-Like Process in Mammary Epithelial Cells MCF10A.
Ordoñez-Moreno A; Rodriguez-Monterrosas C; Cortes-Reynosa P; Perez-Carreon JI; Perez Salazar E
J Cell Biochem; 2017 Sep; 118(9):2983-2992. PubMed ID: 28247960
[TBL] [Abstract] [Full Text] [Related]
13. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
Zhou Y; Lin S; Tseng KF; Han K; Wang Y; Gan ZH; Min DL; Hu HY
BMC Cancer; 2016 Oct; 16(1):818. PubMed ID: 27769200
[TBL] [Abstract] [Full Text] [Related]
14. Expression of Hypoxia-Inducible Factor 1α in Invasive breast cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and epo-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract] [Full Text] [Related]
15. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors timp1, timp2, timp3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract] [Full Text] [Related]
16. Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive breast Carcinomas.
Cid S; Eiro N; González LO; Beridze N; Vazquez J; Vizoso FJ
Clin Breast Cancer; 2016 Aug; 16(4):e83-91. PubMed ID: 27266802
[TBL] [Abstract] [Full Text] [Related]
17. Higher levels of timp-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract] [Full Text] [Related]
18. Expression and characterization of tissue inhibitor of metalloproteinase 4 from complex canine mammary carcinomas.
Kaur N; Sunil Kumar BV; Mahajan K; Singh S
J Immunoassay Immunochem; 2016; 37(5):515-26. PubMed ID: 26979595
[TBL] [Abstract] [Full Text] [Related]
19. Warranting investigation of primary lung adenocarcinoma in patients with an extrapulmonary malignancy and lung nodules due to high frequency.
Zhu B; Dalal S; Kamp DW; Lin X
Am J Clin Pathol; 2014 Mar; 141(3):429-36. PubMed ID: 24515772
[TBL] [Abstract] [Full Text] [Related]
20. Plasma levels of the MMP-9:timp-1 complex as prognostic biomarker in breast cancer: a retrospective study.
Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
[TBL] [Abstract] [Full Text] [Related]
[Next]
